When does dolutegravir’s key patent protection expire?
Dolutegravir’s exact “expire date” depends on the specific patent (and jurisdiction) because multiple patents cover different aspects of the drug (the molecule itself, formulations, combinations, and manufacturing). As a result, there is no single universal expiration date.
How do patent and exclusivity differ for dolutegravir?
Even when a patent term ends, patent-related exclusivity can still differ by country due to:
- additional patents for new uses or formulations,
- product and marketing exclusivities (which are governed by each regulator, not only the patent office),
- and possible patent term adjustments or extensions (varies by jurisdiction).
What determines the expiration date you need?
To give a usable expiration date, you typically need:
- the country/region (e.g., US, EU, UK, India, South Africa),
- the exact patent number or the product/brand you mean (often different filings map to different patent estates),
- whether you mean the earliest patent expiring, or the last blocking patent.
Can generic manufacturers file before patents expire?
In many markets, generic makers can file applications (for example, under regulatory “early entry” pathways), but they usually cannot launch the generic product until the relevant patents/exclusivities expire or are resolved through a legal process.
If you tell me your country, I can narrow it to dates
Share the country (or region) and, if you have it, the patent number (or brand/product label). Then the expiration timeline can be stated for that specific patent family rather than giving a vague generic answer.
Sources
No sources were provided in the prompt, so I can’t cite a specific expiration date.